X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs PANACEA BIOTECH - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS PANACEA BIOTECH IPCA LABS/
PANACEA BIOTECH
 
P/E (TTM) x 28.4 -19.7 - View Chart
P/BV x 3.4 2.3 144.3% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   PANACEA BIOTECH
EQUITY SHARE DATA
    IPCA LABS
Mar-18
PANACEA BIOTECH
Mar-14
IPCA LABS/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs695149 467.7%   
Low Rs40082 486.0%   
Sales per share (Unadj.) Rs260.284.1 309.2%  
Earnings per share (Unadj.) Rs19.0-18.3 -103.6%  
Cash flow per share (Unadj.) Rs33.1-6.7 -493.4%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.083.7 254.5%  
Shares outstanding (eoy) m126.2061.25 206.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.11.4 153.4%   
Avg P/E ratio x28.9-6.3 -457.6%  
P/CF ratio (eoy) x16.6-17.2 -96.1%  
Price / Book Value ratio x2.61.4 186.3%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,1207,074 977.0%   
No. of employees `00013.32.8 482.0%   
Total wages/salary Rs m7,3591,449 507.8%   
Avg. sales/employee Rs Th2,477.41,874.1 132.2%   
Avg. wages/employee Rs Th555.2527.0 105.4%   
Avg. net profit/employee Rs Th180.6-407.7 -44.3%   
INCOME DATA
Net Sales Rs m32,8365,154 637.1%  
Other income Rs m418100 418.8%   
Total revenues Rs m33,2545,254 633.0%   
Gross profit Rs m4,505-766 -587.9%  
Depreciation Rs m1,777711 250.0%   
Interest Rs m2401,503 16.0%   
Profit before tax Rs m2,905-2,881 -100.9%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m51117 3,042.3%   
Profit after tax Rs m2,394-1,121 -213.5%  
Gross profit margin %13.7-14.9 -92.3%  
Effective tax rate %17.6-0.6 -3,016.3%   
Net profit margin %7.3-21.8 -33.5%  
BALANCE SHEET DATA
Current assets Rs m19,4553,810 510.6%   
Current liabilities Rs m10,0768,365 120.4%   
Net working cap to sales %28.6-88.4 -32.3%  
Current ratio x1.90.5 423.9%  
Inventory Days Days98156 62.9%  
Debtors Days Days6767 99.6%  
Net fixed assets Rs m20,26014,480 139.9%   
Share capital Rs m25261 411.7%   
"Free" reserves Rs m26,633903 2,949.1%   
Net worth Rs m26,8865,127 524.4%   
Long term debt Rs m2,3405,832 40.1%   
Total assets Rs m41,17319,433 211.9%  
Interest coverage x13.1-0.9 -1,428.8%   
Debt to equity ratio x0.11.1 7.7%  
Sales to assets ratio x0.80.3 300.7%   
Return on assets %6.42.0 325.8%  
Return on equity %8.9-21.9 -40.7%  
Return on capital %10.83.6 296.0%  
Exports to sales %47.624.5 194.3%   
Imports to sales %14.910.2 146.1%   
Exports (fob) Rs m15,6421,264 1,237.7%   
Imports (cif) Rs m4,884525 930.6%   
Fx inflow Rs m15,6421,539 1,016.2%   
Fx outflow Rs m4,884942 518.4%   
Net fx Rs m10,759597 1,801.5%   
CASH FLOW
From Operations Rs m3,411599 569.3%  
From Investments Rs m-1,354-438 309.2%  
From Financial Activity Rs m-1,304-303 431.0%  
Net Cashflow Rs m753-141 -533.1%  

Share Holding

Indian Promoters % 45.9 74.5 61.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.6 1,900.0%  
FIIs % 25.3 1.3 1,946.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 23.6 73.7%  
Shareholders   36,892 10,259 359.6%  
Pledged promoter(s) holding % 2.1 35.1 6.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  PIRAMAL ENTERPRISES  

Compare IPCA LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Sell-Off; Sensex Slumps Over 530 Points(Closing)

Share markets in India continued their sell-off seen during the last week and ended the day deep in the red. All sectoral indices traded on a negative note.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 24, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - PLETHICO PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS